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Abstract
Objectives: (1) To model the natural history of anal neoplasia in HIV-infected patients using a 3-state Markov model of anal
cancer pathogenesis, adjusting for cytology misclassification; and (2) to estimate the effects of selected time-varying
covariates on transition probabilities.
Design: A retrospective cytology-based inception screening cohort of HIV-infected adults was analyzed using a 3-state
Markov model of clinical pathogenesis of anal neoplasia.
Methods: Longitudinally ascertained cytology categories were adjusted for misclassification using estimates of cytology
accuracy derived from the study cohort. Time-varying covariate effects were estimated as hazard ratios.
Results: (1) There was a moderate to high probability of regression of the high grade squamous intraepithelial lesion (HSIL)
state (27–62%) at 2 years after initial cytology screening; (2) the probability of developing invasive anal cancer (IAC) during
the first 2 years after a baseline HSIL cytology is low (1.9–2.8%); (3) infrared coagulation (IRC) ablation of HSIL lesions is
associated with a 2.2–4.2 fold increased probability of regression to ,HSIL; and (4) antiretroviral therapy, suppressed HIV
plasma viral load, and CD4 $350/mm3 are each associated with reduced probability of progression from ,HSIL to HSIL.
Conclusions: The finding of moderate to high rates of regression of the HSIL state accompanied by low rates of progression
to IAC should inform both screening and precursor treatment guideline development. There appears to be a consistent and
robust beneficial effect of antiretroviral therapy, suppressed viral load, and higher CD4 on the transition from the ,HSIL
state to the HSIL state.
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Introduction
Understanding the natural history and clinical pathogenesis of
anal neoplasia in HIV-infected patients requires both the
availability of longitudinal datasets that capture key transitions
and endpoints as well as analytic methods that take into account
the dynamic nature of the process, involving the possibility of
progression and regression among states of precursors to invasive
anal carcinoma under the influence of identifiable prognostic
factors. We had access to the longitudinal experience of an
inception cohort of HIV-infected adults systematically screened for
invasive anal cancer and its precursor states. The specific aims of
this study were: (1) to model the natural history of anal neoplasia in
HIV-infected patients by estimating cytology-based transition
probabilities and transition rates (per person-year) under a 3-state
model of anal cancer pathogenesis, adjusting for cytology
misclassification; and (2) to estimate the effects of selected time-
varying covariates on transition probabilities: CD4+ lymphocyte
category, HIV plasma viral load suppression, antiretroviral
therapy, smoking, and treatment of anal cancer precursors with
infrared coagulation (IRC).
Methods
In 2001, the University of California San Diego (UCSD) Owen
Clinic implemented systematic screening for anal cancer and its
precursors in all HIV-infected patients under care. The screening
algorithm included baseline anal cytology and digital rectal
examination (DRE) for all patients under care followed by triage
to high resolution anoscopy (HRA) evaluation in patients with
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either anorectal signs or symptoms or abnormal screening cytology
defined as the following Bethesda 2001 cytology diagnostic
categories: atypical squamous cells of uncertain significance
(ASCUS), low grade intraepithelial lesion (LSIL), atypical squa-
mous cells can’t exclude high grade (ASC-H), and high grade
intraepithelial lesion (HSIL) [1]. Anal cytology was obtained using
a moistened Dacron swab and processed using conventional slide
fixation between 2001–2006 and using SurePath liquid cytology
media thereafter. HRA with biopsy was performed by trained
clinicians using methods previously described [2]. Followup
screening with cytology and DRE was recommended annually
by clinic protocol for all patients. Because of limited availability of
HRA-qualified clinicians, patients with HSIL cytology or palpable
abnormalities were preferentially triaged to HRA. Prior to 2007,
treatment for anal cancer precursors was not offered. Starting in
2007, patients with HSIL lesions identified at HRA were offered
the option of ablative treatment using IRC. An evaluation of this
screening program, prior to offering IRC ablation, has been
published [3].
We conducted a retrospective inception cohort analysis of HIV-
infected patients under care at the UCSD Owen Clinic between
2001-2012. Patients were eligible for cohort analysis if they had: (1)
confirmed HIV-infection; and (2) availability of at least 2
longitudinally obtained cytology results (in the absence of a
diagnosis of invasive anal cancer [IAC]) or at least one cytology
result followed by a diagnosis of IAC. Patients were excluded from
cohort analysis if they had: (1) a diagnosis of IAC prior to
screening program entry; (2) treatment for anal cancer precursors
prior to screening program entry.
For each patient, follow-up time began on the date of the first
anal cytology and ended on the first of either the date of IAC
diagnosis or the date of the last anal cytology in the study period.
IAC diagnosis was ascertained by linking the diagnostic database
of the clinic electronic medical record to the UCSD Cancer
Registry and validated by review of histopathology reports.
We defined a 3-state Markov model of IAC pathogenesis
assuming that HSIL is the immediate precursor lesion to invasive
anal cancer [4,5] from which both progression to IAC and
regression to less than HSIL (,HSIL) may occur (Figure 1). IAC
is considered an absorbing state from which regression does not
occur in the absence of definitive treatment. The model state ,
HSIL included the cytologic diagnoses: no atypical or malignant
cells, atypical squamous cells of uncertain significance (ASCUS),
and low grade squamous intraepithelial lesion (LSIL). The HSIL
state included the cytology diagnoses: atypical squamous cells,
can’t rule out high grade (ASC-H) and high grade squamous
intraepithelial lesion (HSIL). Results reported as unsatisfactory or
squamous intraepithelial lesion (SIL) not otherwise specified were
excluded. Cytologic diagnoses were taken as reported by the
UCSD clinical cytopathology laboratory.
The model expresses how patients move between states in
continuous time. At any time, a patient may progress to a more
severe state, or regress to a less severe state as illustrated by the
constraints in Figure 1. This model relies on the standard Markov
assumption that a patient’s risk of transition to another health state
depends only on the health state at the current time [6]. The
model also assumes that transition intensities or rates remain
constant over time, after adjusting for time-varying covariates
which are assumed to be constant between the times they are
observed.
We report estimates of both transition intensities (which may be
interpreted as transition rates per person per year, or hazards) as
well as 2 and 5 year transition probabilities. Since transition
intensities are assumed piecewise-constant over time, they may be
used to estimate a matrix of transition probabilities between
baseline and any future time whose (r,s) entry is defined as the
probability that a patient occupies state s at time t given they are in
state r at baseline. It should be noted, however, that a transition
probability (with the exception of the transition from HSIL to IAC
which is an absorbing state) should not be interpreted as a
cumulative incidence. For example, a patient who transitions from
HSIL at time 0 to,HSIL at time 1 year may have progressed and
regressed between ,HSIL and HSIL any number of times in this
one-year period. However, this is rare in practice.
In order to maintain an inception screening cohort, the model is
cytology based to avoid the selection bias conferred by restricting
analysis to patients who were triaged to undergo HRA with biopsy
because of antecedent HSIL cytology or abnormal DRE. It is
known, however, that both cytology and HRA-directed punch
biopsy are imperfect indicators of true histopathologic severity in
the anal canal [7,8]. We therefore modeled state transitions using
continuous time hidden Markov models, using the R package msm
[9,10], that account for misclassification due to the limitations of
both cytology and HRA-directed punch biopsy. Two cytology
misclassification matrices were defined using results of previous
research from the Owen Clinic anal dysplasia cohort [8]. We first
modeled cytology misclassification assuming a sensitivity (SE [95%
C.I.] = 0.66 [0.50–0.81]) and specificity (SP [95% C.I.] = 0.90
[0.85–0.95]) of cytology against HRA-directed punch biopsy
considered as a gold standard (measured without error). We then
modeled cytology misclassification accounting for the fallibility of
HRA-directed punch biopsy as a reference standard (SE [95%
C.I.] = 0.89 [0.78–0.95], SP [95% C.I.] = 0.96 [0.92–0.98]),
based on extrapolation from the measured sensitivity and
specificity of cervical punch biopsy (with large loop excision of
the cervical transformation zone [LLETZ] histopathology as the
reference standard [11]) and on the assumption of conditional
Figure 1. Three State Markov Model of Clinical Pathogenesis of Anal Neoplasia.
doi:10.1371/journal.pone.0104116.g001
Natural History of Anal Dysplasia
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e104116
independence of cytology and biopsy results given true disease
status. Consistent with recent recommendations for a unified
histopathologic nomenclature for all HPV-associated preinvasive
squamous lesions of the lower anogenital tract [12], we use the
term HSIL (in the context of our own analysis) to refer to cytology
misclassification-adjusted estimates of the true histopathologic
state of the anal canal including the diagnostic categories anal
intraepithelial neoplasia (AIN) 2 and 3. Model goodness-of-fit was
evaluated by graphically comparing observed to expected state
prevalences over a two year period from the initial cytologic
examination.
In order to avoid a form of prevalence-incidence bias [13], we
considered IAC diagnoses within 180 days after the first cytology
result to be prevalent cases and excluded them from the primary
IAC180 analysis. Because the width of this IAC exclusion window
was arbitrarily selected to take into account delays in referral to
HRA and further delays in definitive biopsy of IAC, we performed
a sensitivity analysis that reduced the IAC exclusion window to 30
days after the first cytology result (IAC30 analysis). Final analytic
datasets for both IAC180 and IAC30 analyses are available as a
Supplementary file (Data Analysis File S1.xlsx).
Ethics Statement
This research, including the procedure for documenting patient
consent, was approved by the UCSD Human Research Protection
Program (Project #071931). Written informed consent was
obtained from patients to contribute clinical and laboratory data
collected during routine care under the UCSD Owen Clinic
master protocol.
Results
During the study period (2001–2012), 2804 patients met
eligibility criteria for inclusion in the analysis. Table 1 presents
characteristics of the study participants. Median age was 40 and
11% were female. By race/ethnicity, 30% were black or Hispanic.
Median CD4+ lymphocyte count was 384 (IQR 217–572) cells/
mm3. Compared to demographic characteristics of the entire clinic
population, study participants were more likely to be white (62%
vs. 53%, respectively) and men having sex with men (MSM) who
were not injection drug users (IDU) (78% vs. 62%, respectively).
Three quarters of study participants were on antiretroviral therapy
of whom 64% had a HIV plasma viral load #400 copies/mm3.
Thirty percent were smokers at study entry. Patients were followed
for a median of 4.0 years (IQR 2.0–7.1) and underwent a median
(IQR) of 5 (3–8) longitudinally collected cytology examinations.
Per year of patient followup, the median (IQR) number of
cytologies per patient was 1.1 (0.8–1.5). Eight percent (n = 218)
underwent one or more IRC ablations for HSIL lesions between
2007–2012. Comparing IRC recipients to non-recipients, there
were no differences by age, race/ethnicity, initial CD4 category ($
350 vs.,350 cells/mm3), initial HIV viral load ($400 vs. 400
copies/mm3), or smoking status. IRC recipients were more likely
than non-recipients to be male (95% vs. 88%, p= 0.002) and to
have HSIL as their first cytology result (28% vs. 13%, p,0.0001).
The median number of HSIL cytology results was also greater
among IRC recipients than non-recipients (median [IQR]: 2 [1–4]
vs. 0 [0–1], Wilcoxon rank-sum p,0.0001).
IAC Ascertainment
Thirty five patients were diagnosed with IAC on or after the first
cytology date. Of these, 23 were diagnosed with IAC more than
180 days after the first cytology result and were included in the
IAC180 analysis. An additional 10 IAC diagnoses were made
between 30–180 days after the first cytology and these were
included in the IAC30 analysis (total IAC30 n= 33). Confirmatory
biopsy reports were available for review in 96% of IAC cases.
Markov Model Estimates of 2 and 5-year Transition
Probabilities and Person-Time Rates
Because we found that the time-updated use of IRC was a
significant predictor of the regression of HSIL to less than HSIL
states (see below) and because our first study aim was to
approximate estimates of the natural history of AIN, we present
estimates of transition probabilities standardized to the IRC-
unexposed category (Table 2). The 2-year transition probability of
progression from less than HSIL to HSIL varied from 7–12
percent while the probability of regression of HSIL varied from
27–62 percent depending on cytology misclassification assump-
tions. The wide range of HSIL regression estimates was
determined by cytology misclassification assumptions, with the
higher estimate (62%) associated with the correction of cytology
sensitivity and specificity for the measurement error of the
reference standard punch biopsy. The probability of progression
from HSIL to IAC varied from 1.3% to 2.8% at 2 years and from
2.1% to 5.6% at 5 years. The range of these estimates was
determined more by the width of the IAC exclusion window (#
180, #30 days) than by cytology misclassification assumptions.
Examination of model goodness-of-fit plots showed close approx-
imation between observed and expected state prevalence estimates
through a 5 year modeling timeframe.
Table 3 presents estimates of state transition rates adjusted for
cytology misclassification assumptions and stratified by width of
the IAC exclusion window. These rates may be interpreted as the
risk per person per year of the indicated state transitions,
standardized to the experience of those who never underwent
IRC ablation. The annual rate of progression from ,HSIL to
HSIL varied from 0.04 to 0.11 while the annual rate of regression
of HSIL varied from 0.17 to 0.58. The rate of progression of HSIL
to IAC varied from 0.01 to 0.02.
Covariate effects on State Transition Rates
Table 4 presents unadjusted hazard ratios (HR) for the
following time-updated covariates: (1) IRC ablation, (2) antiretro-
viral therapy, (3) HIV plasma viral load, (4) CD4 category, and (5)
smoking. The hazard ratios are estimated separately for cytology
misclassification assumptions and for width of IAC exclusion
window. As noted above, IRC ablation was strongly associated
with regression of HSIL lesions (HRHSILR,HSIL varying from 2.2
to 4.2). IRC ablation had no statistically significant effect on
progression of HSIL to IAC, but this must be interpreted in the
context of a small number of observed IAC events.
Consistent favorable (protective) effects were observed for
antiretroviral therapy (HR varying from 0.4 to 0.5), suppressed
(#400 copies/mm3) HIV plasma viral load (HR 0.3–0.5), and
higher ($350/mm3) CD4+ lymphocyte category (HR 0.3–0.4) on
the transition from,HSILto HSIL. But these covariates appeared
not to influence regression from HSIL to ,HSIL or progression
from HSIL to IAC. Somewhat surprisingly, we did not observe
effects of smoking on any of the modeled state transitions.
Discussion
This study provides quantitative estimates of the dynamic
natural history of anal intraepithelial neoplasia in a cohort of HIV-
infected patients who were systematically screened for AIN as part
of routine care. Its inferences are based on longitudinal and
repeated cytologic follow-up with careful ascertainment of the
Natural History of Anal Dysplasia
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endpoint invasive anal carcinoma. A particular strength of our
modeling approach is the simultaneous estimation of multiple
dynamic state transition parameters rather than focusing only on
one endpoint (e.g. IAC incidence). Our principal findings are that:
(1) there is a moderate to high probability of regression of HSIL
(27–62%) at 2 years after initial cytology screening; (2) the
probability of developing IAC during the first 2 years after a
baseline HSIL cytology is low (1.9–2.8%); (3) IRC ablation of
HSIL lesions is associated with a 2.2–4.2 fold increased probability
of regression to ,HSIL but not associated with an effect on
progression to IAC; and (4) antiretroviral therapy, suppressed HIV
plasma viral load, and CD4$350/mm3 are each associated with
reduced probability of progression from ,HSIL to HSIL with a
relative risk reduction of progression in the range of 50–70%.
However, there was no discernable effect of these covariates on
either regression of HSIL or progression of HSIL to IAC.
Design-related issues
Interpretation of these findings may be model dependent. Multi-
state Markov models have been used to understand the natural
history of cervical neoplasia [14–17] as well as to model the cost-
effectiveness of screening programs for anal cancer and its
precursors [18–20]. A recent analysis of cervical cytology and
human papilloma virus (HPV) DNA samples in a cohort of HIV-
infected and high risk HIV-negative women used a 3-state
cytology-based Markov model ([1] no SIL, [2] SIL, and [3] the
absorbing state of treatment for SIL or invasive cervical cancer) to
determine factors associated with transitions between cervical
cytopathologic states [21]. In the latter study, SIL was defined, in
the primary analysis, to include ASCUS, LSIL, and HSIL
cytologic findings. Our model focused on HSIL as the putative
necessary precursor lesion to invasive cancer, recognizing that
lower degrees of dysplasia may reflect effects of infection with non-
oncogenic HPV strains (e.g. HPV types 6 and 10).
Table 1. Study Participant Characteristics (n = 2804).
Characteristic n Percent
Age at entry (years Median (IQR)) 40.2 (34.1,46.4)
Sex Female 310 11
Male 2494 89
Race/Ethnicity White 1730 62
Hispanic 490 17
Black 357 13
Other/Unknown 227 8
HIV Risk Factor MSM1 2180 78
IDU2 (not MSM) 133 5
Heterosexual (not IDU) 367 13
Other/Unknown 122 4
Baseline CD4 ,350/mm3 1230 44
$350/mm3 1551 55
missing 23 1
Baseline HIV viral load #400 copies/mm3 1365 49
.400 copies/mm3 1412 50
missing 27 1
On antiretroviral therapy Yes 2807 75
No 707 25
Smoking Yes 837 30
No 1967 70
Baseline cytology result3 NAMC 829 29
ASCUS 919 33
LSIL 663 24
ASC-H 76 3
HSIL 317 11
$1 IRC4 after first cytology Yes 218 8
No 2586 92
No. cytology results/patient Median (IQR) 5 (3,8)
1.MSM: men having sex with men.
2.IDU: injection drug use.
3.NAMC: no atypical or malignant cells; ASCUS: atypical squamous cells of uncertain significance; LSIL: low grade squamous intraepithelial lesion; ASC-H: atypical
squamous cells, can’t exclude high grade; HSIL: high grade squamous intraepithelial lesion.
4.IRC: infrared coagulation.
doi:10.1371/journal.pone.0104116.t001
Natural History of Anal Dysplasia
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e104116
We acknowledge that our decision to classify normal, ASCUS,
and LSIL cytologies as a single state creates heterogeneity as some
patients with normal or ASCUS cytologies may not be HPV-
infected while those with LSIL have at least non-oncogenic strain
infection. However, epidemiological studies have shown that
among HIV-infected MSM, prevalent anal HPV infection is the
rule (.80%) with multiple infecting types also extremely common
(.60%) [22,23]. Oncogenic HPV type 16 is the most common
infecting strain (,30%) and tends to have a lower clearance rate
and higher mean retention time than low risk HPV types [24]. In
addition, incident HPV is common among HIV-infected MSM.
For example, de Pokomandy et al. reported a cumulative
incidence of HPV-16 infection of 33% at 36 months followup in
a cohort of HIV-infected MSM. [22] So while our ,HSIL state is
heterogeneous, even those with normal baseline cytology are likely
to be at risk for either prevalent or incident HPV infection.
Moreover, our research interest focuses especially on those with
HSIL cytology not only because it is the precursor to IAC but also
because current recommendations focus on treatment of HSIL
and not on lower grade lesions [25].
A second study design related issue is our decision to model AIN
natural history using a cytology-based inception cohort rather than
the subset of our cohort that underwent HRA with concurrent
biopsy and cytology. To illustrate the selection factor introduced
by restricting our analysis to the HRA sub-cohort, the proportion
of baseline HSIL cytology among those subsequently referred to
HRA (n= 629) was 38% while the comparable proportion among
those never referred to HRA (n= 2175) was 7% (p,0.0001). This
difference is simply the result of the clinic triage algorithm based
on limited HRA availability. The selection bias introduced by
conditional referral to HRA will be avoided in prospective study
designs that use both cytology and HRA-directed biopsy
concurrently and longitudinally in all screened patients. The
results of one such natural history study are eagerly awaited [26].
A third design issue concerns our methods of adjusting for
cytology misclassification of the true but unknown severity of
histopathologic AIN. Cytology is known to lack sensitivity for
detection of HSIL [7], but as we have argued elsewhere, HRA-
directed punch biopsy is not itself a true gold standard [8]. There
is considerable heterogeneity among reports of anal cytology
sensitivity and specificity with HRA-directed biopsy as the
reference standard and the pooled sensitivity for HSIL on biopsy
using a cytology cut-point of (HSIL or ASC-H) vs (normal,
ASCUS, or LSIL) was only 30% (95% CI: 19–44%) in a recent
meta-analysis [27]. We elected to apply the sensitivity (66%) and
specificity (90%) estimated in our own cohort to correct our state
transition estimates for misclassification due to the limitations of
cytology. We further modeled the implications of taking into
account the fallibility of the punch biopsy reference standard using
a methodology developed to characterize the accuracy of cervical
punch biopsy against a reference standard from LLETZ histopa-
thology [11,28]. Both sets of cytology sensitivity and specificity
modeling assumptions were based on point estimates and do not
take into account imprecision due to sampling variability as
reflected in the width of their respective confidence intervals (see
Results). Some external validation of our misclassification-adjusted
cytology-based methodology may be seen when examining
estimates of progression to and spontaneous regression from HSIL
in an independent longitudinal cohort including both HIV-
infected (73%) and uninfected (27%) patients [29]. In this
Australian cohort report, the state of tissue histopathology was
defined as a composite of the highest grade of cytology or biopsy;
and of 419 patients with baseline cytology, 183 (44%) had biopsy
results. The rate of high grade AIN regression among the HIV-
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infected patients was 19.2 per 100 person-years (p-yrs), which is
very close to our estimate regression rate of 17 per 100 p-yrs
assuming a sensitivity and specificity of cytology of 0.66 and 0.90,
respectively. For the rate of progression from ,HSIL to HSIL,
Tong reported a rate among the HIV-infected of 6.6 per 100 p-
years while our estimate for the same transition was 4 per 100 p-
yrs applying the same cytology misclassification assumption
(Table 3). Estimates in our work based on adjustment for the
fallibility of the punch biopsy as reference standard cannot be
directly compared to those in the Tong paper, which did not make
Table 3. Estimates of State Transition Rate (per person-year) adjusted for Cytology Misclassification Assumptions, by IAC-Exclusion
Window (#180 vs. #30 days)1.
IAC Exclusion Window2
Cytology Misclassification Assumptions (Sensitivity /
Specificity) State Transition Rate (per person-year)3 (95% CI)
,HSIL R HSIL HSIL R ,HSIL HSIL R IAC
#180 days 0.66/0.90 0.04 (0.036–0.054) 0.17 (0.13–0.22) 0.011 (0.007–0.017)
0.89/0.96 0.11 (0.096–0.130) 0.58 (0.50–0.67) 0.011 (0.007–0.016)
#30 days 0.66/0.90 0.04 (0.035–0.053) 0.17 (0.13–0.22) 0.017 (0.012–0.024)
0.89/0.96 0.11 (0.096–0.130) 0.58 (0.50–0.67) 0.016 (0.011–0.023)
1.Model estimates fit with time-updated infrared coagulation (IRC) indicator and standardized to reflect transition rates for those who never underwent IRC. Thus, these
rates estimate the untreated natural history of AIN if the rates remain constant over time and if the Markov assumption is valid.
2.IAC exclusion window: Cases of invasive anal carcinoma (IAC) diagnosed within 180 or 30 days of the first cytology result, respectively, were considered prevalent cases
and were therefore excluded from analysis.
3.State Transitions: HSIL: high grade squamous intraepithelial lesion; IAC: invasive anal carcinoma.
doi:10.1371/journal.pone.0104116.t003
Table 4. Estimated Unadjusted Hazard Ratios (95% CI) of Time-Updated Covariate Effects on State Transitions, by Misclassification
Assumptions and by IAC-Exclusion Window (#180 vs.#30 days).
Covariate
IAC exclusion
window2
Cytology Misclassification Assumptions
(Sensitivity / Specificity) ,HSIL to HSIL HSIL to ,HSIL HSIL to IAC3
1. IRC1 [reference: no IRC] #180 days 0.66/0.90 2.2 (0.6–7.9) 4.2 (2.0–8.5) 2.7 (0.6–11.7)
0.89/0.96 2.1 (0.95–4.6) 2.3 (1.3–4.0) 3.2 (0.7–13.6)
#30 days 0.66/0.90 2.2 (0.6–8.0) 4.2 (2.0–8.6) 1.8 (0.4–7.7)
0.89/0.96 2.1 (0.96–4.7) 2.2 (1.3–3.9) 2.1 (0.5–9.0)
2. ART4 [reference: no ART] #180 days 0.66/0.90 0.4 (0.2–0.6) 0.9 (0.4–2.1) 2.2 (0.5–9.4)
0.89/0.96 0.5 (0.4–0.8) 0.9 (0.6–1.3) 2.1 (0.5–9.1)
#30 days 0.66/0.90 0.4 (0.2–0.6) 0.9 (0.4–2.1) 3.2 (0.8–13.7)
0.89/0.96 0.5 (0.4–0.7) 0.8 (0.6–1.3) 3.2 (0.8–13.4)
3. HIV Viral load [reference:
.400 copies/mm3]
#180 days 0.66/0.90 0.3 (0.2–0.5) 1.3 (0.7–2.3) 1.6 (0.7–3.9)
0.89/0.96 0.5 (0.4–0.7) 1.1 (0.8–1.5) 1.6 (0.6–3.8)
#30 days 0.66/0.90 0.3 (0.2–0.5) 1.3 (0.7–2.3) 1.2 (0.6–2.5)
0.89/0.96 0.5 (0.4–0.7) 1.1 (0.8–1.4) 1.2 (0.6–2.5)
4. CD4 Category [reference:
,350/mm3]
#180 days 0.66/0.90 0.3 (0.2–0.5) 0.8 (0.5–1.3) 1.4 (0.6–3.3)
0.89/0.96 0.4 (0.3–0.6) 0.9 (0.6–1.1) 1.4 (0.6–3.2)
#30 days 0.66/0.90 0.3 (0.2–0.5) 0.8 (0.5–1.3) 1.1 (0.5–2.2)
0.89/0.96 0.4 (0.3–0.6) 0.8 (0.6–1.1) 1.1 (0.5–2.1)
5. Smoking [reference: not
smoking]
#180 days 0.66/0.90 1.1 (0.7–1.7) 0.8 (0.5–1.4) 1.2 (0.5–2.9)
0.89/0.96 1.0 (0.7–1.4) 0.9 (0.7–1.2) 1.3 (0.6–3.0)
#30 days 0.66/0.90 1.1 (0.7–1.7) 0.9 (0.5–1.4) 1.2 (0.6–2.5)
0.89/0.96 1.0 (0.7–1.4) 0.9 (0.7–1.2) 1.3 (0.6–2.6)
1.IRC: infrared coagulation.
2.IAC exclusion window: Cases of invasive anal carcinoma (IAC) diagnosed within 180 or 30 days of the first cytology result, respectively, were considered prevalent cases
and were therefore excluded from analysis.
3.State Transitions: HSIL: high grade squamous intraepithelial lesion; IAC: invasive anal carcinoma.
4.ART: antiretroviral therapy.
doi:10.1371/journal.pone.0104116.t004
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a comparable adjustment. Lacking external validation of estimates
based on adjustment for the fallibility of the punch biopsy as
reference standard, such estimates should be taken with caution.
Estimates of progression to IAC
Risk and rates of progression from HSIL to IAC among HIV-
infected patients who were not treated for HSIL is imprecisely
known. In a recent meta-analysis, Machalek et al. [30] proposed a
theoretical progression rate from high grade AIN to IAC among
HIV-infected men in the HAART era of one in 377 per year in
the absence of treatment for precursor lesions. The few available
longitudinal estimates of the risk and rates of progression from
HSIL to IAC have been recently reviewed [31]. More recently,
Dalla Pria et al. reported on the experience of an HIV-positive
MSM cohort in which HRA with intervention for HSIL was
routinely offered [32]. In this HSIL-treated cohort, the estimated
rate of IAC from first histopathologic diagnosis of high grade AIN
(including AIN-2 and AIN-3) ascertained at the first HRA was 6.1
per 1000 person-years (95% CI: 4.2–7.8); this rate corresponds to
a per person per year rate of 1/164. In comparing estimated rates
of progression from HSIL to IAC, several factors related to the
precise definition of HSIL in its modeling context need to be taken
into account: (1) whether the estimates are based on HSIL
diagnosed at first screening procedure or based on HSIL
diagnosed at baseline or any subsequent screening event; (2)
whether the estimates are based on HSIL diagnosed only by
cytology, only by biopsy, by some combination of cytology and
biopsy, or by misclassification adjusted cytology and biopsy; (3)
whether the estimates are based on baseline HSIL or time updated
HSIL; and (4) what modeling approach is used (e.g. multi-state
modeling, regression modeling). To illustrate the impact of these
factors on HSIL progression estimates, we refer to 2 different
estimates derived from the same cytology-based dataset modeled
in this paper. We estimated using Cox regression analysis the rate
of HSIL progression to IAC, ascertained from the time of the
HSIL cytology at baseline screening (unadjusted for misclassifica-
tion and including data from the 8% of patients who underwent
IRC ablation), as one in 263 per year (95% CI: 1/714–1/222
[Cachay et al., 2014 (submitted)]. In contrast, using Markov
modeling adjusting for cytology misclassification and standardizing
to the experience of patients never exposed to IRC ablation, we
estimated the same progression rate to vary from 1/59 (0.017) to
1/94 (0.011) per person per year depending on the width of the
IAC exclusion window and cytology misclassification assumptions
(Table 3). Clearly it is essential to specify not only the study design
but also the modeling approach when citing HSIL progression
rates.
Covariate effects
A 2012 Cochrane review of interventions for AIN identified
only one randomized controlled trial, of the immunomodulator
imiquimod, that met inclusion criteria and concluded that there
was no reliable evidence for efficacy of any of the examined
interventions [33]. Nonetheless, a number of observational studies
have suggested that IRC ablation of HSIL in HIV-infected
patients is accompanied by frequent recurrence requiring re-
treatment, while the probability of cure of individual HSIL lesions
is high [34–41]. In the absence of randomized controlled trials, it is
not clear that IRC ablation reduces progression to IAC [42]. Our
study confirms a substantial IRC treatment effect (2.2–4.2 fold) in
downgrading HSIL to less than HSIL. However, no statistically
significant effect was observed on the transition probability from
HSIL to IAC.
The effect of highly active antiretroviral therapy (HAART) on
the natural history of AIN and the incidence of IAC in HIV-
infected populations has been recently reviewed [31,43]. It is clear
that the incidence of IAC has increased in the HAART era [44–
46]. Among published studies that have suggested a beneficial
effect of antiretroviral therapy on the natural history of AIN, two
were cross-sectional [47,48] and two longitudinal [49,50]. Among
the cross-sectional studies (both using HRA-directed biopsy),
Wilkin et al. found that current antiretroviral therapy was
associated with lower risk of any degree of AIN while Van der
Snoek et al. found that use of HAART of any duration was
associated with lower risk of any degree of AIN. Among the
longitudinal studies, de Pokomandy et al. found that HAART use
for .4 years was associated with a marginally significant
protective effect (OR, 0.28 [95% CI, 0.07–1.06]) on progression
from ,AIN 2 to AIN 2/3 assessed by HRA while Chiao et al.,
analyzing the Veterans Administration HIV Clinical Case
Registry, found higher proportion of followup time with unde-
tectable HIV plasma viral load predicted lower incidence of IAC.
Our study had the strength of simultaneously examining
longitudinally assessed state transitions in the clinical pathogenesis
of IAC and found a strong protective effect for time-updated
HAART use (50–60% relative risk reduction) not for the transition
of HSIL to IAC or for regression from HSIL to,HSIL, but rather
for progression from ,HSIL to HSIL. This finding was further
supported by our finding that suppressed HIV plasma viral load
and CD4$350, both mediating at least a major part of the benefit
of antiretroviral therapy, also reduced the transition probability
from ,HSIL to HSIL. These findings may be important to
correlate with evolving understanding of the molecular pathogen-
esis of IAC, which seems to involve sequential changes requiring
persistence of oncogenic HPV infection, DNA integration, and
subsequent genetic changes that may be irreversible [51–53].
Smoking is an established cofactor in cervical carcinogenesis
and may act at several steps in the causal pathway leading to
invasive cervical carcinoma [54,55]. Studies have identified
smoking as a risk factor for IAC [56] and for AIN 2+
histopathology [57] among HIV-infected patients. Our failure to
detect a smoking effect on any of the modeled state transitions may
be attributable to ascertainment and misclassification biases since
we relied on electronic medical record diagnoses of smoking rather
than on systematic patient survey of smoking behaviors.
A number of potential data and design limitations of our
analysis have been discussed above, including specification of a 3-
state model, the use of cytology-based state ascertainment, the
impact of cytology misclassification assumptions on model
estimates, and the modeling dependency of estimates of progres-
sion to IAC. In addition, the absence of HPV-DNA screening
limited our ability to identify sub-cohort members most at risk for
progression to HSIL and IAC. Lastly, because of the relatively
small number of IAC endpoints in our cohort, power to detect
covariate effects on the transition from HSIL to IAC is limited.
Conclusions
Analysis of this longitudinal cytology-based misclassification-
adjusted inception screening cohort has yielded simultaneous
quantitative state transition estimates that further elucidate the
clinical pathogenesis of anal neoplasia in HIV-infected patients. Of
particular importance for development of screening and precursor
treatment guidelines is the finding of moderate to high rates of
spontaneous regression of HSIL lesions in association with much
lower rates of progression to invasive anal cancer. This work has
added to evolving understanding of the effects of antiretroviral
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therapy on the natural history of anal neoplasia by identifying
potent preventive effects of HAART, suppressed HIV viral load,
and higher CD4+ lymphocyte category on the transition from ,
HSIL to HSIL. Finally, this analysis supports the effectiveness of
infrared coagulation ablation of HSIL in downgrading HSIL but
detected no effect on progression to invasive cancer.
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